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Background
Atovaquone is a safe, effective antimalarial drug that
inhibits the mitochondrial electron transport chain
(mtETC) of P. falciparum. Clinical resistance is con-
ferred by SNPs in cytochrome b. Although multiple
non-synonymous SNPs can be selected in vitro, thus far
clinical resistance is limited to amino acid substitutions
at position 268 (e.g., Y268S). We are investigating addi-
tional mechanisms by which some isolates of P. falci-
parum became extremely resistant to atovaquone and
other mtETC inhibitors by selecting for in vitro resis-
tance to the dihydroorotate dehydrogenase (DHODH)
inhibitor DSM-1.
Methods
We characterized isolates from patients that failed treat-
ment in atovaquone phase II studies by using a series of
chemotypes that target mitochondrial function. We
defined their structure-activity relationships and observed
broad resistance (5-10,000 fold in atovaquone), suggesting
that cytochrome b mutations alone are not sufficient. We
tested this by selecting for DSM-1 resistance in atova-
quone-susceptible and resistant parasites (paired patient
admission and recrudescent isolates). Following selection,
the parasites were sequenced for mutations in cytochrome
b, DHODH and other candidate mtETC genes.
Results
The extreme atovaquone resistance phenotype accompa-
nies a high-grade resistance to all mtETC inhibitors tested
including DSM-1. Selection studies of atovaquone suscep-
tible parasites rapidly generated resistance in vitro to both
atovaquone and DSM-1 alone (10x IC50 concentration)
yet atovaquone resistant parasites could only generate low
resistance to DSM-1 (2x IC50), and one population
reverted the aa268 mutation to wild-type to cope with
DSM-1 pressure. Furthermore, we successfully recapitu-
lated the clinical Y268S mutation in vitro in TM90-C2A,
the pre-treatment parent for TM90-C2B.
Conclusions
Cytochrome b mutations are not sufficient to explain
extreme mtETC resistance, and selective pressure on the
DHODH enzyme revealed that the Y268S cytochrome b
mutation incurs a fitness cost on the parasite that can-
not be overcome under DSM-1 drug pressure, yet resis-
tance was easily obtained in atovaquone-susceptible
parasites. This suggests that resistance to atovaquone
(Y268S) and DSM-1 are mutually incompatible. Selec-
tion of the Y268S mutation in TM90-C2A indicates that
the parasite genetic background is critical in the selec-
tion of clinical atovaquone resistance, since selection
attempts in multiple other strains results in mutations
in positions other than aa268. Further studies are
required to determine the impact of this phenotype on
the development of new mitochondria-targeted drugs.
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